Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
Tong T. Zhao, Diane Trinh, Christina L. Addison et al. · 2010
Read Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors by Tong T. Zhao, Diane Trinh, Christina L. Addison et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0012563.txt.
Description
Tong Zhao, Diane Trinh, Christina Addison and colleagues paired a cholesterol drug with vessel blockers against cancer, in a 2010 PLOS ONE paper. Lovastatin, a statin, blocks building of mevalonate, a hub molecule in cell chemistry. The team had already seen it hinder the epidermal growth factor receptor; here they tested its action on the VEGF receptor pathway that feeds tumors.
Lovastatin inhibited VEGFR and AKT activation, and combined with VEGFR inhibitors it killed cancer cells synergistically. Repurposing a cheap, safe, off-patent drug as a cancer helper is attractive economics. The pairing now needs animal and clinical tests to see if the dish synergy survives the body.
Catalog record
| CREATOR | Tong T. Zhao, Diane Trinh, Christina L. Addison et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012563